Analysis of apoptosis-related genes in patients with clinically isolated syndrome and their association with conversion to multiple sclerosis

Journal of Neuroimmunology

Volumn 280, Issue , 2015, Pages 43-48

  Hagman, Sanna ^a   Kolasa, Marcin ^a   Basnyat, Pabitra ^a   Helminen, Mika ^a   Kähönen, Mika ^b   Dastidar, Prasun ^b   Lehtimäki, Terho ^a   Elovaara, Irina ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Apoptosis; BCL 2; Biomarkers; Clinically isolated syndrome; Multiple sclerosis

Indexed keywords

DEATH RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; PROTEIN BCL 2; TRANSFORMING GROWTH FACTOR BETA1; CYCLIN D1; CYTOKINE; CYTOSKELETON PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; PYCARD PROTEIN, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNOREGULATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN FAMILY; SIGNAL TRANSDUCTION; DISEASE COURSE; GENETICS; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

ADULT; APOPTOSIS; CASPASE 1; COHORT STUDIES; CYCLIN D1; CYTOKINES; CYTOSKELETAL PROTEINS; DEMYELINATING DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NF-KAPPA B; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84924767384     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.02.006     Document Type: Article

References (30)

1. Achiron A., Feldman A., Mandel M., Gurevich M. Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann. N. Y. Acad. Sci. 2007, 1107:155-167.
2. Bruck W., Gold R., Lund B.T., Oreja-Guevara C., Prat A., Spencer C.M., et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. 2013, 70(10):1315-1324.
3. Chanvillard C., Jacolik R.F., Infante-Duarte C., Nayak R.C. The role of natural killer cells in multiple sclerosis and their therapeutic implications. Front. Immunol. 2013, 4:63.
4. Comabella M., Khoury S.J. Immunopathogenesis of multiple sclerosis. Clin. Immunol. 2012, 142(1):2-8.
5. Comi C., Fleetwood T., Dianzani U. The role of T cell apoptosis in nervous system autoimmunity. Autoimmun. Rev. 2012, 12(2):150-156.
6. Ellwardt E., Zipp F. Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Exp. Neurol. 2014, 262 Pt A: 8-17.
7. Fox E.J., Rhoades R.W. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr. Opin. Neurol. 2012, (25 Suppl.):S11-S19.
8. Freedman M.S. Present and emerging therapies for multiple sclerosis. Continuum (Minneap Minn). Mult. Scler. 2013, 19(4):968-991.
9. Gurevich M., Achiron A. The switch between relapse and remission in multiple sclerosis: continuous inflammatory response balanced by Th1 suppression and neurotrophic factors. J. Neuroimmunol. 2012, 252(1-2):83-88.
10. Hagman S., Raunio M., Rossi M., Dastidar P., Elovaara I. Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study. J. Neuroimmunol. 2011, 234(1-2):141-147.
11. Inoue M., Shinohara M.L. NLRP3 Inflammasome and MS/EAE. Autoimmune Dis. 2013, 2013:859145.
12. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33(11):1444-1452.
13. Lassmann H., Bruck W., Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 2001, 7(3):115-121.
14. Mandel I., Paperna T., Miller A. Aberrant expression of the apoptosis-related proteins BAK and MCL1 in T cells in multiple sclerosis. J. Neuroimmunol. 2012, 244(1-2):51-56.
15. Mc Guire C., Beyaert R., van Loo G. Death receptor signalling in central nervous system inflammation and demyelination. Trends Neurosci. 2011, 34(12):619-628.
16. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50(1):121-127.
17. Meylan F., Richard A.C., Siegel R.M. TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol. Rev. 2011, 244(1):188-196.
18. Miller D.H., Chard D.T., Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012, 11(2):157-169.
19. Moreno M., Negrotto L., Río J., Moubarak R., Martín I., Bustamante M.F., et al. Activation-induced cell death in T lymphocytes from multiple sclerosis patients. J. Neuroimmunol. 2014, 272(1-2):51-55.
20. Oh H., Ghosh S. NF-kappaB: roles and regulation in different CD4(+) T-cell subsets. Immunol. Rev. 2013, 252(1):41-51.
21. Oh S.A., Li M.O. TGF-beta: guardian of T cell function. J. Immunol. 2013, 191(8):3973-3979.
22. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann. Neurol. 2005, 58(6):840-846.
23. Reichardt H.M., Luhder F. The ambivalent role of apoptosis in experimental autoimmune encephalomyelitis and multiple sclerosis. Curr. Pharm. Des. 2012, 18(29):4453-4464.
24. Reuss R., Mistarz M., Mirau A., Kraus J., Bodeker R.H., Oschmann P. FADD is upregulated in relapsing remitting multiple sclerosis. Neuroimmunomodulation 2014, 21(5):221-225.
25. Schuster M., Annemann M., Plaza-Sirvent C., Schmitz I. Atypical IkappaB proteins - nuclear modulators of NF-kappaB signaling. Cell Commun. Signal. 2013, 11(1):23. (-811X-11-23).
26. Semra Y.K., Seidi O.A., Sharief M.K. Disease activity in multiple sclerosis correlates with T lymphocyte expression of the inhibitor of apoptosis proteins. J. Neuroimmunol. 2002, 122(1-2):159-166.
27. Semra Y.K., Seidi O.A., Sharief M.K. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J. Neuroimmunol. 2002, 122(1-2):132-139.
28. Sharief M.K., Semra Y.K. Heightened expression of survivin in activated T lymphocytes from patients with multiple sclerosis. J. Neuroimmunol. 2001, 119(2):358-364.
29. Sharief M.K., Douglas M., Noori M., Semra Y.K. The expression of pro- and anti-apoptosis Bcl-2 family proteins in lymphocytes from patients with multiple sclerosis. J. Neuroimmunol. 2002, 125(1-2):155-162.
30. Sharief M.K., Matthews H., Noori M.A. Expression ratios of the Bcl-2 family proteins and disease activity in multiple sclerosis. J. Neuroimmunol. 2003, 134(1-2):158-165.